Q&A with Alain Litwin, MD, from Albert Einstein College of Medicine: Studying and Overcoming Stigmas of Treating Injectable Drug Users with Hepatitis C

Video

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this, many of these patients do not receive the medications they need to treat their conditions.

One of the largest populations of patients with hepatitis C is those who use injectable drugs. Despite this many of these patients do not receive the medications they need to treat their conditions.

Alain H. Litwin, MD, from the Albert Einstein College of Medicine discussed the results of research done on the topic and what it can mean for providing care for these patients during the annual Liver Meeting in San Francisco.

As hepatitis C becomes a more treatable condition work is being done to extend the treatment to as many patients as possible, including current and former injectable drug users.

Related Videos
Connective Tissue Disease Brings Dermatology & Rheumatology Together
A panel of 4 experts on HIV
A panel of 4 experts on HIV
What Makes JAK Inhibitors Safe in Dermatology
Potential JAK Inhibitor Combination Regimens in Dermatology
Therapies in Development for Hidradenitis Suppurativa
"Prednisone without Side Effects": The JAK Inhibitor Ceiling in Dermatology
Discussing Changes to Atopic Dermatitis Guidelines, with Robert Sidbury, MD, MPH
© 2024 MJH Life Sciences

All rights reserved.